ID: ALA385140

Max Phase: Preclinical

Molecular Formula: C30H26N6O2

Molecular Weight: 502.58

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(-n2nc(C#N)c3ncn(-c4ccc(-c5ccccc5CN5CCCC5)cc4)c(=O)c32)cc1

Standard InChI:  InChI=1S/C30H26N6O2/c1-38-25-14-12-24(13-15-25)36-29-28(27(18-31)33-36)32-20-35(30(29)37)23-10-8-21(9-11-23)26-7-3-2-6-22(26)19-34-16-4-5-17-34/h2-3,6-15,20H,4-5,16-17,19H2,1H3

Standard InChI Key:  CTNVRGOKCPAVEY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 502.58

Molecular Weight (Monoisotopic): 502.2117

AlogP: 4.71

#Rotatable Bonds: 6

Polar Surface Area: 88.97

Molecular Species: BASE

HBA: 8

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 9.65

CX LogP: 4.69

CX LogD: 2.47

Aromatic Rings: 5

Heavy Atoms: 38

QED Weighted: 0.33

Np Likeness Score: -1.21

References

1. Fevig JM, Cacciola J, Buriak J, Rossi KA, Knabb RM, Luettgen JM, Wong PC, Bai SA, Wexler RR, Lam PY..  (2006)  Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.,  16  (14): [PMID:16682200] [10.1016/j.bmcl.2006.04.044]

Source

Source(1):

• Scientific Literature